Most With AD, MCI Would Have Been Excluded From Aducanumab Clinical Trials

Overall, 92.2, 91.0, and 85.5 percent of Medicare beneficiaries with ADRDs, Alzheimer disease, and MCI met at least one of the exclusion criteria

Read More